Search research articles
Contact Us
Filters
Showing results (71-80 of 90) with videos related to
Page
of 9
Sort By:
Cancer Immunology, Immunotherapy : CII
|
June 21, 2022
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Renaud Descourt, Laurent Greillier, Maurice Perol, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 3, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study
Thomas Pierret, Laurent Greillier, Florian Guisier, et al.
Frontiers in Oncology
|
December 15, 2025
Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer
Jean Cabon, Delphine Lerouge, Sebastien Thureau, et al.
Therapeutic Advances in Medical Oncology
|
March 8, 2024
Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)
Jean-Bernard Auliac, Pascal-Alexandre Thomas, Olivier Bylicki, et al.
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Targeted Oncology
|
March 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study
Jean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 29, 2020
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma
Charlotte Domblides, Karen Leroy, Isabelle Monnet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 90) with videos related to
Sort By:
Page
of 9
Cancer Immunology, Immunotherapy : CII
|
June 21, 2022
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Renaud Descourt, Laurent Greillier, Maurice Perol, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 3, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study
Thomas Pierret, Laurent Greillier, Florian Guisier, et al.
Frontiers in Oncology
|
December 15, 2025
Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer
Jean Cabon, Delphine Lerouge, Sebastien Thureau, et al.
Therapeutic Advances in Medical Oncology
|
March 8, 2024
Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)
Jean-Bernard Auliac, Pascal-Alexandre Thomas, Olivier Bylicki, et al.
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Targeted Oncology
|
March 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study
Jean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 29, 2020
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma
Charlotte Domblides, Karen Leroy, Isabelle Monnet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Page
of 9